A Parenting & kids forum. ParentingBanter.com

If this is your first visit, be sure to check out the FAQ by clicking the link above. You may have to register before you can post: click the register link above to proceed. To start viewing messages, select the forum that you want to visit from the selection below.

Go Back   Home » ParentingBanter.com forum » misc.kids » Kids Health
Site Map Home Authors List Search Today's Posts Mark Forums Read Web Partners

[VaxActivists] Shedding of FLUMIST - all flumist - regular and AH1N1



 
 
Thread Tools Display Modes
  #1  
Old October 24th 09, 06:54 PM posted to misc.health.alternative,misc.kids.health
john[_5_]
external usenet poster
 
Posts: 822
Default [VaxActivists] Shedding of FLUMIST - all flumist - regular and AH1N1

May want to go to your schools - superintendents, principals, school boards,
teachers, with this information...................
This should not be given in schools (or stores or anywhere)


THE CDC's Pink Book says in Chapter 10 on Page 142 (if you click on the
Chapter 10 link, it is on page 8 of your PDF but still page 142)
http://www.cdc.gov/vaccines/pubs/pin...nloads/flu.pdf


Publications:



The Pink Book: Chapters
Epidemiology and Prevention of Vaccine Preventable Diseases
Updated 11th Edition, (May 2009)
Vaccinated children can shed vaccine viruses in nasopharyngeal secretions
for up to 3 weeks. One instance of transmission of vaccine virus to a
contact has been documented. The transmitted virus retained its attenuated,
cold-adapted, temperature-sensitive characteristics. The frequency of
shedding of vaccine strains by persons 549 years of age has not been
determined.

*********
http://www.imakenews.com/idf/e_artic....cfm?x=b11,0,w
Q: What are the potential complications of the FluMistT vaccine?
A: The most common adverse events associated with the vaccine in normal
individuals were nasal congestion, runny nose, sore throat and a cough.
Although there is no specific information available, it is anticipated that
if a person with a primary immune deficiency receives FluMistT (s)he would
be more likely to develop complications. If a close contact is vaccinated,
the resulting viral shedding could cause a person with a primary immune
deficiency disease to become infected with the flu vaccine strains. (See A7
below)

Q: What is the risk to individuals with primary immune deficiency disorders
if a close contact is vaccinated with FluMistT?
A: During a clinical trial with FluMistT in a day care center, there was
documented transmission from vaccinated children to unvaccinated children.
Viral shedding following the administration of FluMistT typically continues
for about a week on the average, but may be as long as three weeks. The risk
of transmission in the day care center setting was estimated at 2.4% or one
in approximately 42 children. The risk could be higher if different children
in the center receive the vaccine at different times over the fall.

Healthcare workers who receive FluMistT may also present a possible way for
a person with a primary immune deficiency disease to become infected with
the flu vaccine strains. Although there is no data about transmission of the
live vaccine virus from vacinees to immune compromised contacts and
subsequent development of disease, the Centers for Disease Control and
Prevention have stated that the inactivated vaccine (flu shot) is preferred
over live, intranasal influenza vaccine (FluMistT) for physicians, nurses,
family members, or anyone else coming in close contact with anyone with a
weakened immune system.

School authorities may want to advise their immune deficient pupils if
FluMistT is being administered in the school system. This information may be
especially useful to those with T cell or combined T and B cell immune
deficiencies.

http://www.imakenews.com/idf/e_artic....cfm?x=b11,0,w
Q: How can you reduce your risk of complications from the FluMistT vaccine?
A: To reduce the risk of contracting the flu vaccine strains, the Immune
Deficiency Foundation's Medical Advisory Committee has made the following
recommendations:
a.. Because it is a live virus vaccine, people with primary immune
deficiency diseases should NOT receive the FluMistT vaccine.
b.. The FluMistT vaccine is not recommended for close contacts of primary
immune deficient patients.
c.. Primary immune deficient patients should talk to their doctors to see
if it may be advisable to receive preventive medicine to avoid becoming
infected with the FluMistT strains of the flu.
d.. Primary immune deficient patients exposed through close contact to
FluMistT, should see their doctor immediately, as (s)he may advise a
treatment medicine.
e.. School authorities may want to advise their immune deficient pupils if
FluMistT is being administered in the school system. This information may be
especially useful to those with T cell or combined T and B cell immune
deficiencies.
f.. Family members and healthcare workers in close contact with immune
deficient patients should be advised to receive the killed virus flu shot,
rather than the FluMistT vaccine.


The package insert - they left out the statement that was in the first
insert when it first came out.................now they have all these words
to say possibly shedding up to 21 days but at the end say they don't know.

The original package insert said"
In the section of the FlumMist package insert labeled "PRECAUTIONS," the
manufacturer states the following warning:
"FluMist® recipients should avoid close contact with immunocompromised
individuals for at least 21 days."
The warning is specifically directed toward those living in the same
household with an immunocompromised person, but the on-going release of live
viruses throughout the community may be a significant risk to everyone who
has a weak, or weakened, immune system.

and more from

Risks of FluMist Vaccine by Dr. Sherri Tenpenny
http://www.vaccineinfo.net/immunizat...ne_risks.shtml
The number of immunocompromised people in the United States is enormous:
a.. It is estimated that at least 10%, or more than 28 million people have
eczema. [ 11]
b.. More than 8.5 million people have cancer. [ 12]
c.. There are reported to be 850,000 individuals with diagnosed and
undiagnosed HIV infection or AIDS [ 13] and
d.. Based on 2001 data, there were 184,000 organ recipients [ 14]

An even more extensive list of at-risk people includes the untold millions
on drugs called corticosteroids. Prednisone®, Medrol®, and a variety of
similar medications are given to both adults and children. These drugs are
prescribed for dozens of conditions including asthma; allergies; eczema;
emphysema; Crohn's disease; multiple sclerosis; herniated spinal discs;
acute muscular pain syndromes; and all types of rheumatoid and autoimmune
diseases. As much as 60% of the entire population could be considered to be
"chemically immunosuppressed." It is important to realize that FluMist is
CONTRAINDICATED for people who are immunocompromised. People who receive
FluMist and are living with an immunocompromised person put their loved ones
at risk.



http://gateway.nlm.nih.gov/MeetingAb...102270663.html
shedding info below from 2001

A Randomized, Double-Blind, Placebo-Controlled Trial of the Safety,
Transmissibility and Phenotypic Stability of a Live, Attenuated,
Cold-Adapted Influenza Virus Vaccine (CAIV-T) in Children Attending Day
Care.

VESIKARI T, KARVONEN A, KORHONEN T, EDELMAN K, VAINIONPAA R, SALMI A, FAST
P, TAMIGNIAUX A, SAVILLE M, RAPPAPORT R, ZAMB T, FORREST B; Interscience
Conference on Antimicrobial Agents and Chemotherapy (41st : 2001 : Chicago,
Ill.).
Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob
Agents Chemother. 2001 Dec 16-19; 41: abstract no. G-450.

Univ. Tampere, Tampere, Finland

BACKGROUND: CAIV-T has been shown to be efficacious and effective in healthy
children and adults. This study was designed to estimate the frequency at
which CAIV-T vaccine viruses may be transmitted between children in day
care. METHODS: 197 children aged /=8 to 36 mos. attending day care were
randomized to receive a single intranasal dose of either 10[7] TCID[50] of
each CAIV-T strain (n = 98) or placebo (n = 99). Viral shedding was
determined for 21 days by culture of nasal swabs. Vaccine virus was
identified by type and subtype, and analyzed for cold-adapted (ca)
temperature-sensitive (ts) phenotype. Subjects were monitored for
reactogenicity events (predefined events within 21 days of dosing). Serious
adverse events were collected for a 42-day period. RESULTS: 80% of CAIV-T
recipients shed /=1 vaccine strain (32% A/H1N1; 12% A/H3N2; 74% influenza
B); 6% shed two A strains; and 6% shed all 3 strains. Mean shedding duration
was 7.6 days (A/H1N1: 5.3; A/H3N2: 8.5; B: 7.0). One placebo recipient shed
influenza B vaccine virus, confirmed by phenotype and genotype analysis,
indicating transmission. Estimated transmission rate was 1.75% for the
evaluable analysis population (90% CI upper bound: 8.05%). The ca ts
phenotype of all shed vaccine viruses was preserved. There were no
statistically significant differences in reactogenicity episodes between
study groups. CONCLUSION: CAIV-T was well tolerated in young children aged
/=8 to 36 mos. CAIV-T may be transmitted between young children in close

contact, with an estimated rate of 1.75% (90% CI: 8.05%). All shed and
transmitted virus retained the ca ts phenotype.


http://www.fda.gov/downloads/Biologi.../UCM182406.pdf
14.5 Transmission Study
FluMist contains live attenuated influenza viruses that must infect and
replicate in cells lining the nasopharynx of the recipient to induce
immunity. Vaccine viruses capable of infection and replication can be
cultured from nasal secretions obtained from vaccine recipients. The
relationship of viral replication in a vaccine recipient and transmission of
vaccine viruses to other individuals has not been established.
Using the frozen formulation, a prospective, randomized, double-blind,
placebo-controlled trial was performed in a daycare setting in children 3
years of age to assess the transmission of vaccine viruses from a vaccinated
individual to a non-vaccinated individual. A total of 197 children 8-36
months of age were randomized to receive one dose of FluMist (n=98) or
placebo (n=99). Virus shedding was evaluated for 21 days by culture of nasal
swab specimens. Wild-type A (H3N2) influenza virus was documented to have
circulated in the community and in the study population during the trial,
whereas Type A (H1N1) and Type B strains did not.

At least one vaccine strain was isolated from 80% of FluMist recipients;
strains were recovered from 1-21 days post vaccination (mean duration of 7.6
days ± 3.4 days). The cold-adapted (ca) and temperature-sensitive (ts)
phenotypes were preserved in 135 tested of 250 strains isolated at the local
laboratory. Ten influenza isolates (9 influenza A, 1 influenza B) were
cultured from a total of seven placebo subjects. One placebo subject had
mild symptomatic Type B virus infection confirmed as a transmitted vaccine
virus by a FluMist recipient in the same playgroup. This Type B isolate
retained the ca, ts, and att phenotypes of the vaccine strain, and had the
same genetic sequence when compared to a Type B virus cultured from a
vaccine recipient within the same playgroup. Four of the influenza Type A
isolates were confirmed as wild-type A/Panama (H3N2). The remaining isolates
could not be further characterized.
Assuming a single transmission event (isolation of the Type B vaccine
strain), the probability of a young child acquiring vaccine virus following
close contact with a single FluMist vaccinee in this daycare setting was
0.58% (95% CI: 0, 1.7) based on the Reed-Frost model. With documented
transmission of one Type B in one placebo subject and possible transmission
of Type A viruses in four placebo subjects, the probability of acquiring a
transmitted vaccine virus was estimated to be 2.4% (95% CI: 0.13, 4.6),
using the Reed-Frost model.

The duration of FluMist vaccine virus replication and shedding have not been
established.

and in section
5.4 Altered Immunocompetence
Administration of Influenza A (H1N1) 2009 Monovalent Vaccine Live,
Intranasal, or FluMist live virus vaccine, to immunocompromised persons
should be based on careful consideration of potential benefits and risks.
Although FluMist was studied in 57 asymptomatic or mildly symptomatic adults
with HIV infection [see Clinical Studies (14.3)], data supporting the safety
and effectiveness of FluMist administration in immunocompromised individuals
are limited.

ONLY TO BE GIVEN to immunocompromised with careful consideration and
shedding to all is exposing all.



 




Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

vB code is On
Smilies are On
[IMG] code is On
HTML code is Off
Forum Jump

Similar Threads
Thread Thread Starter Forum Replies Last Post
FluMist was HYPING VACCINES: AN INVESTIGATION Todd Gastaldo Kids Health 0 October 19th 04 06:02 AM
FluMist or FluZone nasal vaccine for children? sams Kids Health 4 December 12th 03 05:30 AM
'1918' (also: FluMist: Attn Safeway/Albertson Shoppers) Todd Gastaldo Pregnancy 0 October 30th 03 11:22 PM
Truly dangerous and hyped up FluMist Maryilee Kids Health 6 October 20th 03 12:22 PM
[OT] When Does the Shedding Slow Down? Belphoebe Breastfeeding 10 July 21st 03 02:21 PM


All times are GMT +1. The time now is 08:31 PM.


Powered by vBulletin® Version 3.6.4
Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.
Copyright ©2004-2024 ParentingBanter.com.
The comments are property of their posters.